These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 16316856)

  • 1. Reversible Z-E isomerism and pharmaceutical implications for SU5416.
    Sistla A; Shenoy N
    Drug Dev Ind Pharm; 2005 Dec; 31(10):1001-7. PubMed ID: 16316856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous determination of Z-3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-2-indolinone (SU5416) and its interconvertible geometric isomer (SU5886) in rat plasma by LC/MS/MS.
    Zhao Y; Sukbuntherng J
    J Pharm Biomed Anal; 2005 Jul; 38(3):479-86. PubMed ID: 15925249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analytical aspects of sunitinib and its geometric isomerism towards therapeutic drug monitoring in clinical routine.
    Posocco B; Buzzo M; Giodini L; Crotti S; D'Aronco S; Traldi P; Agostini M; Marangon E; Toffoli G
    J Pharm Biomed Anal; 2018 Oct; 160():360-367. PubMed ID: 30119000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous determination of Z-SU5416 and its interconvertible geometric E-isomer in rat plasma by LC/MS/MS.
    Zhao Y; Sukbuntherng J; Antonian L
    J Pharm Biomed Anal; 2004 May; 35(3):513-22. PubMed ID: 15137976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-performance liquid chromatographic method for determination of reversible isomers of SU5416.
    Sistla A; Yang WL; Shenoy N
    J Chromatogr A; 2006 Mar; 1110(1-2):73-80. PubMed ID: 16472814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry.
    de Bruijn P; Sleijfer S; Lam MH; Mathijssen RH; Wiemer EA; Loos WJ
    J Pharm Biomed Anal; 2010 Mar; 51(4):934-41. PubMed ID: 19931354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous determination of SU5416 and its phase I and phase II metabolites in rat and dog plasma by LC/MS/MS.
    Zhao Y; Yang CY; Haznedar J; Antonian L
    J Pharm Biomed Anal; 2001 Jul; 25(5-6):821-32. PubMed ID: 11377065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sunitinib loaded chitosan nanoparticles formulation and its evaluation.
    Joseph JJ; Sangeetha D; Gomathi T
    Int J Biol Macromol; 2016 Jan; 82():952-8. PubMed ID: 26522243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma and cerebrospinal fluid pharmacokinetics of SU5416 after intravenous administration in nonhuman primates.
    Renbarger J; Aleksic A; McGuffey L; Dauser R; Berg S; Blaney S
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):39-42. PubMed ID: 14551735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determinants for in vivo antitumor effect of angiogenesis inhibitor SU5416 formulated in PEGylated emulsion.
    Ogawara K; Abe S; Un K; Yoshizawa Y; Kimura T; Higaki K
    J Pharm Sci; 2014 Aug; 103(8):2464-9. PubMed ID: 24985750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of SU5416, a novel angiogenesis inhibitor, in human plasma by liquid chromatography.
    Tohnya TM; Kim S; Fine HA; Dunn L; Figg WD; Sparreboom A
    J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Jun; 805(1):135-40. PubMed ID: 15113549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiangiogenic cancer therapy using tumor vasculature-targeted liposomes encapsulating 3-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one, SU5416.
    Katanasaka Y; Ida T; Asai T; Shimizu K; Koizumi F; Maeda N; Baba K; Oku N
    Cancer Lett; 2008 Nov; 270(2):260-8. PubMed ID: 18555591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of an intravenous formulation of SU010382 (prodrug of SU5416, an anti-angiogenesis agent).
    Sistla A; Kertelj A; Shenoy N
    PDA J Pharm Sci Technol; 2008; 62(3):200-10. PubMed ID: 18661869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies.
    Stopeck A; Sheldon M; Vahedian M; Cropp G; Gosalia R; Hannah A
    Clin Cancer Res; 2002 Sep; 8(9):2798-805. PubMed ID: 12231519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-activity-relationship studies of conformationally restricted analogs of combretastatin A-4 derived from SU5416.
    Pandit B; Sun Y; Chen P; Sackett DL; Hu Z; Rich W; Li C; Lewis A; Schaefer K; Li PK
    Bioorg Med Chem; 2006 Oct; 14(19):6492-501. PubMed ID: 16860559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of light sources on sunitinib measurements with photoisomerization.
    Matsunaga N; Kitahara T; Yamada M; Sato K; Kodama Y; Sasaki H
    Biomed Chromatogr; 2019 Feb; 33(2):e4407. PubMed ID: 30315654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Actinometric and Φ-order photodegradation properties of anti-cancer Sunitinib.
    Maafi M; Lee LY
    J Pharm Biomed Anal; 2015 Jun; 110():34-41. PubMed ID: 25796061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function.
    Mendel DB; Schreck RE; West DC; Li G; Strawn LM; Tanciongco SS; Vasile S; Shawver LK; Cherrington JM
    Clin Cancer Res; 2000 Dec; 6(12):4848-58. PubMed ID: 11156244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of light intensity, n-alcohols, water-soluble colorants, and solution viscosity on photoisomerization of sorivudine.
    Desai D; Li D; Janjikhel R; Lang B; Jain N
    Pharm Dev Technol; 2001; 6(1):99-106. PubMed ID: 11247280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiRNA-21 silencing mediated by tumor-targeted nanoparticles combined with sunitinib: A new multimodal gene therapy approach for glioblastoma.
    Costa PM; Cardoso AL; Custódia C; Cunha P; Pereira de Almeida L; Pedroso de Lima MC
    J Control Release; 2015 Jun; 207():31-9. PubMed ID: 25861727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.